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A “seesaw effect” in methicillin-resistant Staphylococcus aureus (MRSA) has been demonstrated, whereby susceptibility to
-lactam antimicrobials increases as glyco- and lipopeptide susceptibility decreases. We investigated this effect by evaluating the
activity of the anti-MRSA cephalosporin ceftaroline against isogenic pairs of MRSA strains with various susceptibilities to vanco-
mycin in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model. The activities of ceftaroline at 600 mg every 12 h
(q12h) (targeted free maximum concentration of drug in serum [fCmax], 15.2 g/ml; half-life [t1/2], 2.3 h) and vancomycin at 1 g
q12h (targeted fCmax, 18 g/ml; t1/2, 6 h) were evaluated against 3 pairs of isogenic clinical strains of MRSA that developed in-
creased MICs to vancomycin in patients while on therapy using a two-compartment hollow-fiber PK/PD model with a starting
inoculum of 107 CFU/ml over a 96-h period. Bacterial killing and development of resistance were evaluated. Expression of pen-
icillin-binding proteins (PBPs) 2 and 4 was evaluated by reverse transcription (RT)-PCR. The achieved pharmacokinetic param-
eters were 98 to 119% of the targeted values. Ceftaroline and vancomycin were bactericidal against 5/6 and 1/6 strains, respec-
tively, at 96 h. Ceftaroline was more active against the mutant strains than the parent strains, with this difference being
statistically significant for 2/3 strain pairs at 96 h. The level of PBP2 expression was 4.4 higher in the vancomycin-intermediate
S. aureus (VISA) strain in 1/3 pairs. The levels of PBP2 and PBP4 expression were otherwise similar between the parent and mu-
tant strains. These data support the seesaw hypothesis that ceftaroline, like traditional -lactams, is more active against strains
that are less susceptible to vancomycin even when the ceftaroline MICs are identical. Further research to explore these unique
findings is warranted.
Ceftaroline (CPT) is an anti-methicillin-resistant Staphylococ-cus aureus (anti-MRSA) cephalosporin approved by the U.S.
Food and Drug Administration as the prodrug ceftaroline-fosamil
(CPT-F) for the treatment of community-acquired bacterial
pneumonia and acute bacterial skin and skin structure infections.
CPT inhibits cell wall synthesis by irreversibly binding penicillin-
binding proteins (PBPs) 1 to 3, including the mutated PBP2a,
which confers methicillin resistance, but like most -lactams,
CPT has minimal affinity for PBP4 (1–4). CPT maintains activity
against MRSA isolates with reduced susceptibility to vancomycin
(VAN) and daptomycin (DAP), including heteroresistant VAN-
intermediate S. aureus (hVISA), VISA, VAN-resistant S. aureus
(VRSA), and DAP-nonsusceptible S. aureus (DNSSA) (5, 6). Ex-
periments evaluating CPT activity in a previously described in
vitro pharmacokinetic/pharmacodynamic (PK/PD) hollow fiber
model against MRSA isolates with reduced susceptibility to VAN
or DAP have suggested CPT may exhibit enhanced activity against
hVISA and VISA compared to that in VAN-susceptible S. aureus
(VSSA) (7, 8). Although this observation was unrelated to the
objectives of these studies, it was noted with all of the hVISA and
VISA strains, with the exception of Mu3, which is not susceptible
to CPT.
The previously described “seesaw” effect in MRSA, in which
isolates show increased oxacillin (OXA) susceptibility as VAN sus-
ceptibility decreases, may contribute to the enhanced bactericidal
activity of CPT against hVISA and VISA isolates (9, 10). While the
exact mechanism for increases in OXA susceptibility in the pres-
ence of the mecA gene is not fully elucidated, genetic and/or met-
abolic modifications in the expression or nature of PBPs due to
VAN or DAP pressure may contribute (11). Comparisons of both
unrelated clinical strains and in vitro-derived pairs have revealed a
decrease or absence of PBP4 in VISA strains compared to VAN-
susceptible MRSA (11–13). Studies examining both in vitro and
clinical pairs have found increases in either the amount of PBP2,
levels of expression of PBPs, or degree of PBP2 activity in VISA or
VISA-like strains compared to those in VAN-susceptible S. aureus
strains (13–15). A decrease in PBP4, to which CPT has minimal
affinity, coupled with the increase in PBP2, to which CPT has high
affinity, may explain the enhanced activity of -lactams, including
CPT, in hVISA and VISA strains.
The objective of the present study was to investigate the poten-
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tial enhanced activity of CPT against MRSA strains with reduced
susceptibility to VAN and/or DAP. This was accomplished by
comparing the difference in killing by CPT in isogenic strain pairs
that vary only in their susceptibility to VAN and DAP in a two-
compartment hollow fiber PK/PD model and by quantifying
changes in PBP2 and PBP4 expression between these strains.
MATERIALS AND METHODS
Bacterial strains. Three isogenic clinical MRSA strain pairs, which devel-
oped reduced susceptibility to VAN in vivo in patients on therapy with
VAN or DAP, were evaluated. The hVISA strain Mu3 was used as a refer-
ence strain for population analysis experiments as previously described
(16). The VISA strain Mu50 was also included in the CPT population
analysis experiments as a comparator. The strain information is summa-
rized in Table 1.
Antimicrobials and media. CPT was provided by its manufacturer
(Forest Laboratories, Inc., New York, NY). VAN and DAP were commer-
cially purchased (Sigma-Aldrich Co., St. Louis, MO, and Cubist Pharma-
ceuticals, Lexington, MA, respectively). Mueller-Hinton broth (MHB;
Difco, Detroit, MI) with 25 mg/liter calcium and 12.5 mg/liter magnesium
was used for all in vitro experiments. MHB supplemented to 50 mg/liter of
calcium was used for DAP MIC testing. Colony counts were determined
using tryptic soy agar (TSA; Difco) plates. Brain heart infusion agar
(BHIA; Difco) plates, supplemented with VAN or CPT, were used for
resistance screening and population analysis experiments. Antibiotic me-
dium agar 11 (Difco, Detroit, MI) was used for bioassays performed for
pharmacokinetic analysis.
Susceptibility testing. The MICs of study antimicrobial agents were
determined by broth microdilution (BMD) according to Clinical and
Laboratory Standards Institute (CLSI) guidelines and by Etest (17). All
samples were incubated at 35°C for 24 h before the MICs were read.
Modified PAP. A bacterial suspension of 1  108 CFU/ml was plated
with an automatic spiral-plating device (WASP; DW Scientific, West
Yorkshire, United Kingdom) onto freshly prepared BHIA plates contain-
ing 0.06 to 2.5 g/ml of CPT or 0.25 to 8 g/ml of VAN (7, 16). After 48
h of incubation at 35°C, colony counts were determined using an auto-
mated colony counter (ProtoCOL; Synoptics, Ltd., Frederick, MD). The
lower limit of detection for colony counts is 2 log10 CFU/ml. Colony
counts were plotted against increasing concentrations of VAN or CPT,
and the areas under the curve (AUC) of the resultant curves were calcu-
lated using SigmaPlot (version 10.0; Systat Software, Inc., San Jose, CA).
For VAN population analysis profiles (PAPs), AUC ratios were calculated
by dividing the AUC of the test organism by the AUC of hVISA strain
Mu3, which was determined on the same day. Any strain with an AUC
ratio of 0.9 was considered positive for the hVISA phenotype (16).
In vitro PK/PD model. An in vitro two-compartment hollow fiber
PK/PD model (model C2011; Fiber Cell Systems, Inc., Frederick, MD)
was utilized, inoculated, and maintained as previously described (7).
Fresh medium was continuously supplied and removed from the central
compartment along with the drug via a peristaltic pump (Masterflex;
Cole-Parmer Instrument Company, Chicago, IL) set to simulate the av-
erage human half-lives (t1/2) of the antibiotics. The antibiotic regimens
were free drug simulations of CPT-F at 600 mg every 12 h (q12h) (t1/2, 2.3
h; targeted free maximum concentration of drug in serum [fCmax], 15.2
g/ml; protein binding, 20%), and VAN at 1,000 mg q12h (t1/2, 6 h;
targeted fCmax, 18 g/ml; protein binding, 50%). A drug-free growth con-
trol was also run for each strain. All model tests were performed in dupli-
cate to ensure reproducibility.
Pharmacodynamic analysis. Samples from each model were collected
at 0, 4, 8, 24, 28, 32, 48, 56, 72, and 96 h in duplicate and diluted in cold
0.9% saline. Colony counts were performed as previously described
(7). Changes in log10 CFU/ml were plotted against time to construct
curves to describe the antibacterial activities of the simulated regi-
mens. Bactericidal activity (99.9% kill) was defined as a 3-log10-
CFU/ml decrease in colony count from the initial inoculum. Bacterio-
static activity was defined as a 3-log10-CFU/ml reduction in colony
count from the initial inoculum, while inactivity was defined as no
observed reduction in initial inoculum.
Pharmacokinetic analysis. Duplicate pharmacokinetic samples were
obtained and stored as previously described (7). CPT and VAN concen-
trations were determined by bioassay and fluorescence polarization im-
munoassay (TDX assay; Abbott Diagnostics), respectively, using previ-
ously described methods (7, 18). The intraday coefficients of variation for
the VAN and CPT assays are 2.5% and 10%, respectively, for high,
medium, and low standards. The half-lives, area under the curve (AUC),
and peak concentrations of the antibiotics were determined by the trape-
zoidal method utilizing PK Analyst software (version 1.10; MicroMath
Scientific Software, Salt Lake City, UT).
Resistance. Emergence of resistance was evaluated at multiple time
points throughout the simulation by plating 100-l samples from each
time point on BHIA plates supplemented with CPT or VAN at a concen-
tration 3 the MIC of the tested antibiotic. Plates were examined for
growth after 24 and 48 h of incubation at 35°C.
Determination of PBP expression levels in isogenic organism pairs.
Expression levels of PBP2 and PBP4 were determined by quantitative
RT-PCR in the strains with reduced susceptibility to VAN and compared
to those of the isogenic parent strain by previously described methods
(19). Briefly, each strain was grown overnight in MHB supplemented with
0.5 the MIC of VAN. Cells from overnight cultures were used to inoc-
ulate 50 ml of Mueller-Hinton broth, and the cells were allowed to grow to
an optical density at 550 nm (OD550) of 0.4 and harvested by centrifuga-
tion. Total RNA was isolated from cell pellets of the isogenic strain pairs
and immediately incubated with 1 ml RNAprotect (Qiagen, Valencia,
CA). Total RNA was isolated using a Purescript RNA isolation kit (Gentra,
Minneapolis, MN) according to the manufacturer’s instructions. Quan-
titative RT-PCR was performed using a one-step RT-PCR kit (Qiagen)
following the manufacturer’s recommended protocol. TaqMan probes
and primers for PBP2 and PBP4 were designed using Beacon Designer
7.80 (Premier Biosoft International, Palo Alto, CA) and were purchased
commercially (Eurofins MWG/Operon, Huntsville, AL). 16S RNA was
used as a housekeeping gene control. Each reaction was performed in
triplicate. PBP transcription was considered to be induced or downregu-
lated when mRNA was present at a level at least 4-fold higher or lower than
that of the corresponding MRSA parent strain (19).
Statistical analysis. Changes in log10 CFU/ml at 24, 48, 56, 72, and 96
h were compared by one-way analysis of variance (ANOVA). A P value of
0.05 was considered significant. All statistical analyses were performed
using SPSS statistical software (release 20.0; SPSS, Inc., Chicago, IL).
TABLE 1 Vancomycin phenotypes, susceptibilities, and population
analyses of the strains tested in this study
Strain Phenotype






JH1 VSSA 1 (2) 0.5 (0.5) 0.25 (0.38) 0.8247 7.95
JH9 VISA 8 (8) 0.5 (0.5) 1 (1.5) NP 7.45
R6911 hVISA 2 (4) 0.5 (0.5) 2 (1.5) 1.2528 10.13
R6913 VISA 4 (8) 0.5 (0.5) 4 (8) NP 8.99
T51643 VSSA 1 (2) 1 (1) 0.5 (0.5) 0.774 12.21
H9749-2 hVISA 2 (3) 1 (0.5) 0.5 (1.5) 1.167 10.32
Mu3 hVISA 2 (3) 2 (1.5) 1 13.42
Mu50 hVISA 4 (4) 1 (0.75) NP 8.16
a The AUC ratio is relative to the PAP AUC of Mu3. A VAN PAP AUC ratio of 0.9 is
considered positive for the hVISA phenotype. Vancomycin population analysis was not
performed (NP) on known VISA strains.
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FIG 1 Activity of simulated drug regimens tested against each isogenic strain pair in the in vitro hollow fiber PK/PD model.
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RESULTS
Susceptibility and population analysis data for each pair are sum-
marized in Table 1. The CPT MICs were 0.5 or 1 g/ml, with no
differences between the parent and mutant strains for any of the
three isogenic pairs by standard BMD methods. VAN MICs were 1
or 2 g/ml in parents and increased to 2 to 8 g/ml in VISA and/or
hVISA derivatives by standard BMD methods. DAP MICs were
0.25/1 g/ml, 2/4 g/ml, and 0.5/0.5 g/ml for the parent/deriv-
ative isogenic strain pairs, respectively, by standard BMD meth-
ods. Etest MICs were higher than the BMD values for VAN but
were similar for CPT and DAP.
The average observed fCmax values for VAN and CPT were
21.5  0.2 g/ml (target, 18 g/ml) and 14.63  0.3 g/ml (tar-
get, 15.2 g/ml), respectively. The average observed half-lives for
VAN and CPT were 5.4  0.16 h (target, 6 h) and 2.27  0.26 h
(target, 2.3 h), respectively. The VAN fAUC0 –24 was 218  3.25
mg · h/ml. For CPT, the free-drug times above the MIC were
91.35% of the dosing interval for the strains with a MIC of 0.5
g/ml and 72.5% for the strains with a MIC of 1 g/ml.
Bacterial survival against each antimicrobial regimen over time
for each strain pair is summarized in Fig. 1A to C. CPT was signif-
icantly more active against the mutant strain than the parent
strain by 96 h in 2/3 pairs and maintained bactericidal activity
against 5/6 strains by 96 h. VAN was bacteriostatic against 5/6
strains by 96 h. VAN, at a simulated dose of 1 g intravenous (i.v.)
every 12 h, was less active than CPT in this model against all strains
except for one VAN-susceptible MRSA strain (T-51643). VAN
was significantly more active against JH1 (MIC, 1 g/ml) than its
VISA mutant, JH9 (MIC, 8 g/ml), and was somewhat more ac-
tive against T-51643 than its hVISA derivative, H9749-2, but was
similarly active against the hVISA-VISA pair R6911 and R6913.
The emergence of resistance was not detected from any of the
models.
VAN PAP was conducted on non-VISA strains in order to
identify hVISA. R6911 and H9749-2 were both positive for the
hVISA phenotype, as indicated by a PAP AUC ratio to hVISA
control strain Mu3 of 0.9 (Table 1) (16). CPT population anal-
ysis was also performed in order to describe heterogeneous sus-
ceptibility to CPT (Fig. 2). Values representing heterogeneity of
susceptibility to CPT and VAN, reported as PAP AUC or AUC
ratios to Mu3, are listed in Table 1. The CPT AUC values were
higher in the more VAN-susceptible than in the less-susceptible
mutant strain in each pair. A larger difference in CPT AUC be-
tween parent and mutant strains seemed to correlate with a larger
difference in CPT killing in the model; however, there was poor
correlation between CPT AUC and killing when all strains were
compared in all models.
PBP4 was expressed to a lesser extent in the strain with reduced
susceptibility to VAN in each pair; however, this difference was
too small (4-fold) to be considered a substantial change in ex-
pression. JH1 expressed 1.3 times more PBP4 than JH9, R6911
expressed 1.1 times more PBP4 than R6913, and T51643 expressed
2 times more PBP4 than H9749-2. PB2 expression was substan-
tially induced in JH9 relative to that in JH1 but was moderately
downregulated in the mutant strains of the other pairs. PBP2 was
expressed 4.4 times higher in JH9 than in JH1, but expression was
63% lower in R6913 than that in R6911 and 28% lower in H9749-2
than that in T51643.
DISCUSSION
The inverse correlation between -lactam susceptibility and lipo-
and glycopeptide susceptibility in MRSA, known as the seesaw
effect, has been shown to affect traditional antistaphylococcal
-lactams. However, it is unknown whether this relationship
holds true for the anti-MRSA cephalosporin CPT. In this study,
we evaluated differences in CPT activity in closely related isolates
that differed only in the susceptibilities to VAN and DAP. Inter-
estingly, in all three pairs the mutant and the parent strain had the
same CPT MIC. We demonstrated that CPT was significantly
more active against MRSA strains with reduced susceptibility to
VAN relative to their more susceptible parent strains for 2/3 pairs
tested, despite the fact that both parent and mutant strains had the
same CPT MIC. This observation supports the hypothesis that
CPT is also affected by the seesaw effect and may be more active
against strains with a higher VAN and/or DAP MIC. Even though
there was not a measurable difference in the CPT MIC for the
mutant versus the parent strain in any of the pairs, using a popu-
lation analysis profile to characterize less-susceptible subpopula-
tions we revealed that mutant strains were more uniformly sus-
ceptible than their corresponding parent strains, as evidenced by
their lower CPT PAP AUC. The relative decrease in heterogeneity
between the parent and mutant strains seemed to be proportional
to the increased level of killing observed in the model. However,
there was a poor correlation between the log10-CFU/ml reduction
in bacterial load and the CPT PAP AUC across all strains (data not
shown). The simulated CPT regimen resulted in greater bacterial
killing than the simulated VAN regimen against all strains, except
for T51643 (MRSA). It is interesting to note that this strain was the
most susceptible to VAN (VAN MIC, 1 g/ml; VAN PAP AUC
ratio, 0.77) and the least susceptible to CPT (CPT MIC, 1 g/ml;
CPT PAP AUC, 12.21). The improved activity of CPT simulations
FIG 2 Ceftaroline population analysis profile for various strains tested in this
study. Shown are the ceftaroline population analysis profiles for Mu3 (hVISA;
VAN MIC, 2 g/ml; CPT MIC, 2 g/ml), JH1 (VSSA; VAN MIC, 1 g/ml;
CPT MIC, 0.5 g/ml), JH9 (VISA; VAN MIC, 8 g/ml; CPT MIC, 0.5 g/ml),
R6911 (hVISA; VAN MIC, 2 g/ml; CPT MIC, 0.5 g/ml), R6913 (VISA; VAN
MIC, 4 g/ml; CPT MIC, 0.5 g/ml), T51643 (VSSA; VAN MIC, 1 g/ml; CPT
MIC, 1 g/ml), and H9749-2 (hVISA; VAN MIC, 2 g/ml; CPT MIC, 1
g/ml).
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relative to VAN was not surprising, as the VAN exposures in the
model were only optimized for the two VSSA strains with MICs of
1 g/ml. Suboptimal VAN exposure in this model does not allow
for clinical extrapolation of the comparison between CPT and
VAN; however, this was not the goal of this experiment.
The improvement in CPT killing against less-susceptible
strains was not associated with a substantial reduction in tran-
scription of PBP4, as was hypothesized. The expected increase in
PBP2 expression in VAN nonsusceptible strains was only ob-
served between JH1 and JH9. Other investigators have shown that
PBP2 and PBP2a are both induced in the presence of cell wall
active agents, including VAN and OXA (15, 20). While some have
suggested that reduction of PBP4 transcription plays an important
role in the expression of the VISA phenotype, others have found
that PBP4, as well as other PBP subtypes, may be increased or
unchanged in glycopeptide-nonsusceptible strains (11, 12, 21). It
is possible that differential PBP expression is a common but not
universal mechanism for reduced VAN susceptibility and the see-
saw effect. Further research is warranted to clarify the role of vari-
able PBP expression in glycopeptide-nonsusceptible strains.
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